GlaxoSmithKline PLC (LON:GSK) has won US regulatory approval for two new ways of administering a treatment for severe asthma.
The Food & Drug Administration gave the green light for GSK’s Nucala to be given using an auto-injector or a pre-filled safety syringe.
This means patients or their carers will now be able to inject it. Currently, Nucala, which is for people with severe eosinophilic asthma, is available from doctors in a powder version.
"Nucala's efficacy is well-established and this approval means that, for the first time, we are able to provide patients living with these debilitating conditions the option of receiving this important medicine in their own home,” said Dr Hal Barron, GSK’s chief medical officer.